Keywords: u3, pharma, achieves, proof-of-concept, u3-1287, germany, translational

U3 Pharma achieves proof-of-concept on U3-1287

Article | 21 April 2008

Germany's U3 Pharma, a translational medicine-focused oncology company, says that preclinical proof-of-concept has been established for its lead product U3 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Amgen

Go to company listing